Company registration number 07938267 (England and Wales)
EXROID TECHNOLOGY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
EXROID TECHNOLOGY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
EXROID TECHNOLOGY LIMITED
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
17,098
16,431
Tangible assets
5
58,743
65,205
Investments
200
200
76,041
81,836
Current assets
Stocks
51,496
56,944
Debtors
454,603
265,595
Cash at bank and in hand
74,771
18,732
580,870
341,271
Creditors: amounts falling due within one year
(1,832,402)
(1,367,645)
Net current liabilities
(1,251,532)
(1,026,374)
Total assets less current liabilities
(1,175,491)
(944,538)
Creditors: amounts falling due after more than one year
6
(612,082)
(495,911)
Net liabilities
(1,787,573)
(1,440,449)
Capital and reserves
Called up share capital
7
73,668
73,638
Share premium account
1,876,480
1,876,480
Profit and loss reserves
(3,737,721)
(3,390,567)
Total equity
(1,787,573)
(1,440,449)

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

EXROID TECHNOLOGY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2025
31 March 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 11 August 2025 and are signed on its behalf by:
Lisa Ellerker
Director
Company registration number 07938267 (England and Wales)
EXROID TECHNOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information

eXroid Technology Limited is a private company limited by shares incorporated in England and Wales. The registered office is Innovation House, Ramsgate Road, Sandwich, Kent, CT13 9ND.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account discounts and refunds.

 

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Research and development expenditure

Research and development is written off against profits in the year in which it is incurred.

1.4
Intangible fixed assets

Intangible assets are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website
over 5 years
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
over 5 years and 15% on reducing balance
Fixtures and fittings
15% on reducing balance
Computers
25% on cost
EXROID TECHNOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and direct manufacturing costs.

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances are measured at transaction price.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans are recognised at transaction price.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised at transaction price.

EXROID TECHNOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 5 -
1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
13
15
EXROID TECHNOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
4
Intangible fixed assets
Total
£
Cost
At 1 April 2024
26,670
Additions
7,000
At 31 March 2025
33,670
Amortisation and impairment
At 1 April 2024
10,238
Amortisation charged for the year
6,334
At 31 March 2025
16,572
Carrying amount
At 31 March 2025
17,098
At 31 March 2024
16,431
5
Tangible fixed assets
Total
£
Cost
At 1 April 2024
130,335
Additions
27,598
Disposals
(15,356)
At 31 March 2025
142,577
Depreciation and impairment
At 1 April 2024
65,131
Depreciation charged in the year
20,882
Eliminated in respect of disposals
(2,179)
At 31 March 2025
83,834
Carrying amount
At 31 March 2025
58,743
At 31 March 2024
65,205
EXROID TECHNOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
6
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
1,667
11,667
Other creditors
460,415
334,244
Accruals and deferred income
150,000
150,000
612,082
495,911
7
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
73,668
73,638
73,668
73,638
8
Related party transactions

During the year the director, Dr. M Hudson-Peacock received a repayment of loans of £nil (2024: £nil) to the company. This therefore leaves total loans from the director, Dr. M Hudson-Peacock, at the year-end of £42,144 (2024: £35,938). Interest has been charged to the company at an agreed rate of interest, totalling £6,206 (2024: £1,892) and is included in these accounts under non-bank interest on loans. In addition, there are three loans due to Hudson-Peacock Investments Limited, the first being for £254,609 (2024: £217,113), a further loan made in 2020/21 of £215,00078,404 outstanding at the year-end (2024: £114,611)), replacing the previous Lloyds bank loan, and a loan of £200,000 made in 2024/25. Repayments for these loans totals £38,861 (2024: £32,882). Interest has been charged to the company at an agreed rate of interest totalling £40,149 (2024: £14,668) and is included in these accounts under non-bank interest on loans. The director, Dr. M Hudson-Peacock is also a director of Hudson-Peacock Investments Limited. There is a further amount of £90,000 (2024: £90,000) included within accrued expenses which relates to the amount due to Hudson-Peacock Investments Limited.

9
Going concern

The accounts have been prepared on a going concern basis, despite having net liabilities, as the directors intend to to continue to support the company and the entity will also be supported by other group companies.

2025-03-312024-04-01falsefalsefalse11 August 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityGraham  BasonLisa EllerkerDr Mark Hudson-PeacockMichael WilshawBonney HallettStephen Jones079382672024-04-012025-03-31079382672025-03-31079382672024-03-3107938267core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3107938267core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3107938267core:Non-currentFinancialInstrumentscore:AfterOneYear2025-03-3107938267core:Non-currentFinancialInstrumentscore:AfterOneYear2024-03-3107938267core:Non-currentFinancialInstruments2025-03-3107938267core:Non-currentFinancialInstruments2024-03-3107938267core:ShareCapital2025-03-3107938267core:ShareCapital2024-03-3107938267core:SharePremium2025-03-3107938267core:SharePremium2024-03-3107938267core:RetainedEarningsAccumulatedLosses2025-03-3107938267core:RetainedEarningsAccumulatedLosses2024-03-3107938267core:ShareCapitalOrdinaryShareClass12025-03-3107938267core:ShareCapitalOrdinaryShareClass12024-03-3107938267bus:Director22024-04-012025-03-3107938267core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3107938267core:PlantMachinery2024-04-012025-03-3107938267core:FurnitureFittings2024-04-012025-03-3107938267core:ComputerEquipment2024-04-012025-03-31079382672023-04-012024-03-31079382672024-03-3107938267core:Non-currentFinancialInstruments12025-03-3107938267core:Non-currentFinancialInstruments12024-03-3107938267bus:OrdinaryShareClass12024-04-012025-03-3107938267bus:OrdinaryShareClass12025-03-3107938267bus:OrdinaryShareClass12024-03-3107938267bus:PrivateLimitedCompanyLtd2024-04-012025-03-3107938267bus:FRS1022024-04-012025-03-3107938267bus:AuditExemptWithAccountantsReport2024-04-012025-03-3107938267bus:Director12024-04-012025-03-3107938267bus:Director32024-04-012025-03-3107938267bus:Director42024-04-012025-03-3107938267bus:Director52024-04-012025-03-3107938267bus:Director62024-04-012025-03-3107938267bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3107938267bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP